The Premier Gathering for the Life Science Anti-Corruption Community

The 18th Annual FCPA & Anti-Corruption for the Life Sciences Industry is the premier event for legal and compliance professionals from pharmaceutical, medical device, CRO, and biotechnology companies to connect, compare notes and expand their networks.

The 2023 program will stand apart, featuring practical, carefully researched content based on our key findings from multiple conversations with life sciences anti-corruption players. Our experts will probe only the most cutting-edge strategies and emerging trends.

2023 Government Faculty
Speaker Name

Derek Ettinger

Assistant Chief, FCPA Unit
Fraud Section, Criminal Division

U.S. Department of Justice

2023 Conference Co-chairs
Speaker Name

Mara Senn

Executive Global Compliance Leader, GE Healthcare
Former Trial Attorney, Criminal Division
U.S. Department of Justice

Speaker Name

Adam Yoffie

Senior Corporate Counsel, Litigation and Government Investigations, Bristol Myers Squibb
Former Trial Attorney, Criminal Division
U.S. Department of Justice

Featured Speakers
Speaker Name

Gwen Chapman

Chief Compliance Officer
Illumina, Inc.

Speaker Name

Marc Hennes

Head of Legal Investigations
Novartis

Speaker Name

Susan Lipsitz

Vice President, Associate General Counsel, and Chief Compliance Officer
IQVIA

Speaker Name

Ashley Watson

General Counsel, Medical Devices
Johnson & Johnson

Speaker Name

Lilian Lustre

Head of Ethics and Business Integrity
LATAM, Sanofi

FRESH TOPICS FOR 2023
  • Asia’s Fast-Changing Life Sciences Business Landscape: The Top 5 Most Vexing Questions and Practical Tips for Navigating Grey Areas
  • Ephemeral Messaging: DOJ’s Increased Oversight and Navigating WeChat Communication Landmines
  • The Effectiveness of Compliance Programs: Real-World Takeaways Amid the Latest DOJ Enforcement Posture
  • Employee Compensation and Clawbacks: Compliance Program Best Practices Amid Increased DOJ Oversight
  • New Challenges for Brazil and the Life Sciences Industry: Market Entry Due Diligence Amid a Political Polarization
  • The Africa Opportunity: Market Growth Drivers, Entry Challenges, and What it Takes to Win
  • Engaging with Foreign Governments: Third-Party Intermediary Due Diligence and Gaining Access to Government Formularies
ACI Insights

Tips for Entering the Life Sciences Market in Brazil

For life sciences companies, Brazil’s market offers both an abundance of business opportunities and a myriad of on-the-ground regulatory compliance challenges for new entrants. Getting the market-entry strategy right will mean the difference between success or failure.

Benefit from 1:1, large and smaller-group networking and benchmarking with senior in-house decision-makers from pharmaceutical, biotech and medical device companies, and CROs! Compare notes, share “war stories” and hear lessons learned for mitigating heightened global compliance risks.

Join the go-to event of the year for the life sciences industry!

CLE Accreditation

Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.

Learn more